Correction to: Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: A systematic review of the world literature (BMC Med. (2016) 14 (10) DOI: 10.1186/s12916-016-0553-2);Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: A systematic review of the world literature

BMC Medicine

Volumn 14, Issue 1, 2016, Pages

  Onakpoya, Igho J ^a   Heneghan, Carl J ^a   Aronson, Jeffrey K ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Adverse drug reaction; Drug withdrawal; Systematic review; Voluntary recall

Indexed keywords

DRUG; ERGOMETRINE;

ADVERSE DRUG REACTION; AFRICA; ARTICLE; ASIA; AUSTRALIA; CARCINOGENICITY; CARDIOTOXICITY; DRUG ABUSE; DRUG CARCINOGENICITY; DRUG DEPENDENCE; DRUG FATALITY; DRUG WITHDRAWAL; EUROPE; GEOGRAPHIC DISTRIBUTION; HEMATOLOGIC DISEASE; HUMAN; LIVER TOXICITY; NEUROTOXICITY; NONHUMAN; PACIFIC ISLANDS; SYSTEMATIC REVIEW (TOPIC); WESTERN HEMISPHERE; AUSTRALIA AND NEW ZEALAND; DRUG RECALL; DRUG SURVEILLANCE PROGRAM; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EVIDENCE BASED MEDICINE; FACTUAL DATABASE; PUBLICATION; STANDARDS; STATISTICS AND NUMERICAL DATA;

ADVERSE DRUG REACTION REPORTING SYSTEMS; AFRICA; AMERICAS; ASIA; AUSTRALASIA; DATABASES, FACTUAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EUROPE; EVIDENCE-BASED MEDICINE; HUMANS; OCEANIA; PUBLICATIONS; SAFETY-BASED DRUG WITHDRAWALS;

EID: 84959338530     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/s12916-019-1294-9     Document Type: Erratum

References (53)

1. Furberg CD. Understanding drug safety and how to maximize it for patients. JAAPA. 2011;24:16.
2. Sullivan JW. A pharmaceutical manufacturer's perspective on reporting adverse drug experiences. Am J Hosp Pharm. 1990;47:1342-5.
3. Anonymous. New contraindication added to Reclast drug label. Reactions Weekly. 2011;1368:3.
4. Thomas SK, Hodson J, McIlroy G, Dhami A, Coleman JJ. The impact of direct healthcare professional communication on prescribing practice in the UK hospital setting: an interrupted time series analysis. Drug Saf. 2013;36:557-64.
5. Eyal N. Reconciling informed consent with prescription drug requirements. J Med Ethics. 2012;38:589-91.
6. Food and Drug Administration. Regulatory Procedures Manual - October 2013. Chapter 7 Recall Procedures. http://www.fda.gov/downloads/ICECI/ComplianceManuals/RegulatoryProceduresManual/UCM074312.pdf. Accessed 20 Mar 2015.
7. Onakpoya IJ, Heneghan CJ, Aronson JK. Delays in the post-marketing withdrawal of drugs to which deaths have been attributed: a systematic investigation and analysis. BMC Med. 2015;13:26.
8. Talbot J, Waller P, editors. Stephens' Detection of New Adverse Drug Reactions. 5th ed. Chichester: John Wiley and Sons Ltd; 2004.
9. Pharmaceutical Manufacturing Encyclopedia. Norwich, NY: William Andrew Publishing; 2007.
10. The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals. Whitehouse Station, NJ: Merck Sharp & Dohme Corp, a subsidiary of Merck & Co, Inc.; 2013.
11. Siramshetty VB, Nickel-Seeber J, Omieczynski C, Gohlke B-O, Drwal MN, Preissner R. WITHDRAWN-a resource for withdrawn and discontinued drugs Nucleic Acids Res (Database issue 2015); NAR. http://cheminfo.charite.de/withdrawn/. Accessed Nov-Dec, 2015.
12. Medicines and Healthcare products Regulatory Authority. A guide to what is a medicinal product. MHRA Guidance Note No. 8. Revised November 2012. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/398998/A_guide_to_what_is_a_medicinal_product.pdf. Accessed 12 Oct 2014.
13. OCEBM Levels of Evidence Working Group. The Oxford 2011 Levels of Evidence. Oxford Centre for Evidence-Based Medicine. http://www.cebm.net/index.aspx?o=5653. Accessed 18 Jun 2015.
14. WHO Collaborating Centre for Drug Statistics Methodology. Complete ATC/DDD Index 2008. http://www.whocc.no/atc_ddd_index/. Accessed 21 Apr 2013.
15. Isah AO, Pal SN, Olsson S, Dodoo A, Bencheikh RS. Specific features of medicines safety and pharmacovigilance in Africa. Ther Adv Drug Saf. 2012;3:25-34.
16. Nwokike J, Choi HL. Safety of medicines in sub-Saharan Africa: assessment of pharmacovigilance systems and their performance. Africa Pharmacovigilance Meeting: Ensuring quality and safety of medicines in sub-Saharan Africa. Nairobi, Kenya: 2012. https://africapv2012.files.wordpress.com/2012/05/day-1_2_findings-from-the-ssa-study_nwokike.pdf. Accessed 26 Nov 2015.
17. Appiah B. Africa struggles to improve drug safety. CMAJ. 2012;184:E533-4.
18. Loke YK, Price D, Derry S, Aronson JK. Case reports of suspected adverse drug reactions - systematic literature survey of follow-up. BMJ. 2006;332:335-9.
19. World Health Organization. African Medicines Agency: Setting Milestones Towards its Establishment, 1 April 2014. AUC/WHO/2014/Doc.2. Geneva: WHO; 2014.
20. Menkes DB. Hazardous drugs in developing countries. BMJ. 1997;315:1557-8.
21. Whitehead M, Dahlgren G, Evans T. Equity and health sector reforms: can low-income countries escape the medical poverty trap? Lancet. 2001;358:833-6.
22. Saini P, Loke YK, Gamble C, Altman DG, Williamson PR, Kirkham JJ. Selective reporting bias of harm outcomes within studies: findings from a cohort of systematic reviews. BMJ. 2014;349:g6501.
23. Public Citizen. Petition to Ban the Diet Drug Sibutramine (Meridia). http://www.fda.gov/ohrms/dockets/dailys/02/Mar02/032202/02p-0120_cp00001_vol1.pdf. Accessed 11 Apr 2015.
24. Saito M, Hirata-Koizumi M, Miyake S, Hasegawa R. Withdrawal of cerivastatin revealed a flaw of post-marketing surveillance system in the United States. Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku. 2005;123:41-5.
25. Anonymous. US pharmacovigilance system in need of an overhaul? Reactions Weekly. 2004;1029:3.
26. Williams D, Feely J. Underreporting of adverse drug reactions: attitudes of Irish doctors. Ir J Med Sci. 1999;168:257-61.
27. Martin RM, Kapoor KV, Wilton LV, Mann RD. Underreporting of suspected adverse drug reactions to newly marketed ("black triangle") drugs in general practice: observational study. BMJ. 1998;317:119-20.
28. Brvar M, Fokter N, Bunc M, Mozina M. The frequency of adverse drug reaction related admissions according to method of detection, admission urgency and medical department specialty. BMC Clin Pharmacol. 2009;9:8.
29. Pérez García M, Figueras A. The lack of knowledge about the voluntary reporting system of adverse drug reactions as a major cause of underreporting: direct survey among health professionals. Pharmacoepidemiol Drug Saf. 2011;20:1295-302.
30. Vallano A, Cereza G, Pedròs C, Agustí A, Danés I, Aguilera C, et al. Obstacles and solutions for spontaneous reporting of adverse drug reactions in the hospital. Br J Clin Pharmacol. 2005;60:653-8.
31. Irujo M, Beitia G, Bes-Rastrollo M, Figueiras A, Hernández-Díaz S, Lasheras B. Factors that influence under-reporting of suspected adverse drug reactions among community pharmacists in a Spanish region. Drug Saf. 2007;30:1073-82.
32. Hasford J, Goettler M, Munter KH, Müller-Oerlinghausen B. Physicians' knowledge and attitudes regarding the spontaneous reporting system for adverse drug reactions. J Clin Epidemiol. 2002;55:945-50.
33. Pedrós C, Vallano A, Cereza G, Mendoza-Aran G, Agustí A, Aguilera C, et al. An intervention to improve spontaneous adverse drug reaction reporting by hospital physicians: a time series analysis in Spain. Drug Saf. 2009;32:77-83.
34. Lopez-Gonzalez E, Herdeiro MT, Piñeiro-Lamas M, Figueiras A, GREPHEPI group. Effect of an educational intervention to improve adverse drug reaction reporting in physicians: a cluster randomized controlled trial. Drug Saf. 2015;38:189-96.
35. Herdeiro MT, Ribeiro-Vaz I, Ferreira M, Polónia J, Falcão A, Figueiras A. Workshop- and telephone-based interventions to improve adverse drug reaction reporting: a cluster-randomized trial in Portugal. Drug Saf. 2012;35:655-65.
36. Figueiras A, Herdeiro MT, Polónia J, Gestal-Otero JJ. An educational intervention to improve physician reporting of adverse drug reactions: a cluster-randomized controlled trial. JAMA. 2006;296:1086-93.
37. Biagi C, Montanaro N, Buccellato E, Roberto G, Vaccheri A, Motola D. Underreporting in pharmacovigilance: an intervention for Italian GPs (Emilia-Romagna region). Eur J Clin Pharmacol. 2013;69:237-44.
38. Tapsfield J, Mathews T, Lungu M, van Oosterhout JJ. Underreporting of side effects of standard first-line ART in the routine setting in Blantyre. Malawi Malawi Med J. 2011;23:115-7.
39. Kiguba R, Karamagi C, Waako P, Ndagije HB, Bird SM. Recognition and reporting of suspected adverse drug reactions by surveyed healthcare professionals in Uganda: key determinants. BMJ Open. 2014;4:e005869.
40. Avery AJ, Anderson C, Bond CM, Fortnum H, Gifford A, Hannaford PC, et al. Evaluation of patient reporting of adverse drug reactions to the UK Yellow Card Scheme: literature review, descriptive and qualitative analyses, and questionnaire surveys. Health Technol Assess. 2011;15:1-234.
41. Furberg BD, Furberg CD. How are adverse drug reactions measured? In: Furberg BD, Furberg CD, editors. Evaluating Clinical Research: All that glitters is not gold. New York: Springer Science + Business Media, LLC; 2007. p. 67-71.
42. Khan LM, Al-Harthi SE, Osman AM, Sattar MA, Ali AS. Dilemmas of the causality assessment tools in the diagnosis of adverse drug reactions. Saudi Pharm J. 2015. doi: 10.1016/j.jsps.2015.01.010.
43. United States Food and Drug Administration. Summary of NDA Approvals & Receipts, 1938 to the present. http://www.fda.gov/%20AboutFDA/WhatWeDo/History/ProductRegulation/SummaryofNDAApprovalsReceipts1938tothepresent/default.htm#Notes. Accessed 25 Nov 2015.
44. Rawson NS. New drug approval times and safety warnings in the United States and Canada, 1992-2011. J Popul Ther Clin Pharmacol. 2013;20:e67-81.
45. McNaughton R, Huet G, Shakir S. An investigation into drug products withdrawn from the EU market between 2002 and 2011 for safety reasons and the evidence used to support the decision-making. BMJ Open. 2014;4:e004221.
46. Fung M, Thornton A, Mybeck K, Wu J, Hornbuckle K, Muniz E. Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets -1960 to 1999. Drug Inf J. 2001;35:293-317.
47. Abraham J, Davis C. A comparative analysis of drug safety withdrawals in the UK and the US (1971-1992): implications for current regulatory thinking and policy. Soc Sci Med. 2005;61:881-92.
48. Ninan B, Wertheimer A. Withdrawing drugs in the US verses other countries. Innov Pharm. 2012;3:1-12.
49. Bakke OM, Wardell WM, Lasagna L. Drug discontinuations in the United Kingdom and the United States, 1964 to 1983: Issues of safety. Clin Pharmacol Ther. 1984;35:559-67.
50. World Health Organization. List of Globally identified Websites of Medicines Regulatory Authorities. http://www.who.int/medicines/areas/quality_safety/regulation_legislation/ListMRAWebsites.pdf. Accessed 25 Nov 2015.
51. NHS Choices. The Antibiotic Awareness Campaign. http://www.nhs.uk/NHSEngland/ARC/Pages/AboutARC.aspx. Assessed 6 Mar 2015.
52. Auta A, Omale S, Folorunsho TJ, David S, Banwat SB. Medicine vendors: self-medication practices and medicine knowledge. N Am J Med Sci. 2012;4:24-8.
53. Bamgboye EA, Amoran OE, Yusuf OB. Self medication practices among workers in a tertiary hospital in Nigeria. Afr J Med Sci. 2006;35:411-5.